Urology

Results showed that US overestimated bladder volumes compared to CBCT, with an average deviation of 60.75 ml.

Profiling urine tumour DNA at baseline and after 3 months of treatment could identify whether patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer might not benefit from systemic immunotherapy.

These insights are particularly relevant in minimally invasive surgery, where precision and confidence are vital.

The GETSBI study is not only crucial for this specific patient group but also holds broader implications for research in rare, chronic conditions.

Preliminary outcomes indicated that AE may improve haemoglobin levels, possibly counteracting androgen deprivation therapy induced reductions.

The guidelines endorse adjuvant nivolumab for patients with pT3/4 and/or pN+ disease who are unsuitable for, or have declined, cisplatin-based chemotherapy.

Importantly, 30% mean reductions in prostate volume were sustained up to 18 months post-procedure.

Insomnia appeared in 61%, cognitive impairment and irritability in 38%, and more severe psychiatric issues such as psychosis and delirium were rarely considered.